Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results

Gharbiya, Magda; Allievi, Francesca; Mazzeo, Luigi; Gabrieli, C. Balacco

doi:10.1016/j.ajo.2008.07.022

Cited by 105 publications

(106 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, lower dose levels of 1 and 1.25 mg intravitreous bevacizumab were reported and had favourable results in 1-year follow-up. 8,9 However, more frequent injections were noted. Further studies for comparing the frequency of injections using different dose levels are necessary.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Chen

2009

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (P ¼ 0.017). The final mean central retinal thickness was 214.1 ± 36.3 lm, with a mean decrease of 59.8 lm from the pretreatment value (P ¼ 0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Chen

2009

Eye

View full text Add to dashboard Cite

show abstract

“…[21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends. Of all studies examined, a total of 181 eyes received treatment for naïve lesions, and 74 eyes were treated earlier.…”

Section: Pathological Myopiamentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

“…12 O bevacizumab é um anticorpo monoclonal, humanizado, recombinante, 33 desenvolvido para tratamento endovenoso, como adjuvante da quimioterapia, na terapia de neoplasias sólidas metastizadas. Assume particular interesse no tratamento da NVC na miopia, pelos resultados promissores descritos em séries de casos e alguns ensaios clínicos, 1,6,8,11,13,[34][35][36] aliados a um preço significativamente mais baixo quando comparado com o ranibizumab, permitindo deste modo que a terapêutica seja acessível a um maior número de doentes. 10 Verificámos que os agentes antiangiogénicos permitiram uma melhoria significativa e sustentada na MAVC e na EF, até aos 60 meses de tratamento.…”

Section: Discussionunclassified

“…Os nossos resultados estão de acordo com outros descritos para o ranibizumab [37][38][39][40][41] e para o bevacizumab em estudos com menor tempo de seguimento. 36,42 A variação da MAVC relativamente ao valor inicial foi progressivamente menor para os diferentes tempos de seguimento, embora sempre superiores à MAVC inicial (p < 0,05), o que poderá ser explicado pela idade mais avançada, com componente associado de DMI e consequentemente MAVC mais baixas, bem como pela progressão da atrofia associada à miopia e à própria NVC. Por sua vez, a variação na EF foi progressivamente maior, o que poderá estar relacionado não só com a redução do edema macular, mas também com a atrofia corioretiniana nos doentes miópicos.…”

Section: Discussionunclassified

“…Apesar de a idade ser um importante fator prognósti-co, com influência na história natural da doença após tratamento com anti VEGF, 10,36 não foi associada de forma significativa aos resultados da acuidade visual (p > 0,05). Os nossos achados podem dever-se ao facto de a maioria dos doentes ter mais de 50 anos (65,5%), com idade média de 57,2 (+-16,1).…”

Section: Discussionunclassified

See 1 more Smart Citation

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

et al. 2014

View full text Add to dashboard Cite

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods:In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results:The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

show abstract

Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results

Cited by 105 publications

References 34 publications

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Contact Info

Product

Resources

About